ArticlePloS one2024
Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress on Extracellular Matrix-Based Composite Materials in Antibacterial Field.Biomaterials research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a mathematical model to predict the release profile and antibacterial efficacy of a vancomycin delivery system integrated with poly(L-lactic acid)-coated bone implants specifically designed for bone plates. Using Fickian diffusion principles within an ANSYS-CFX computational fluid dynamic model, we validated the model against our in vitro vancomycin release and agar diffusion studies, as well as previously published in vivo data, confirming the reliability of the model. The model predictions demonstrated the effectiveness of the system in inhibiting bacterial growth in surrounding tissue with no observed toxicity, with a peak vancomycin concentration of 0.95 mg/ml at 6 hours, followed by a decrease to levels that remained effective for antibacterial activity. Furthermore, a sensitivity analysis revealed that the model is particularly sensitive to the half-life of vancomycin, with a maximum sensitivity index of 0.8, indicating its greater impact on the prediction accuracy than the diffusion coefficient, which has a maximum sensitivity index of 0.5. Therefore, precise input of vancomycin's half-life is critical for accurate predictions. These findings offer substantial support for the efficacy of the local delivery system as a promising therapeutic approach against implant-associated infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.